Compare Cassava Sciences Inc (FLNA) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $58.82 (market cap $75.38B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 1418.5× Cassava Sciences Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.41% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MDLZ | |
|---|---|---|
Market Cap | $53.14M | $75.38B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $70.75 |
52-Week Low | $1.09 | $51.51 |
Enterprise Value | -$33.43M | $95.47B |
Dividend Yield | — | 3.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Mondelez International (MDLZ) trades at $60.48, up 2.86% with a bearish technical signal despite recent earnings beats. The company reported 2025 revenue of $38.54B with a net income margin of 6.64%, while valuation ratios like P/E of 29.07 suggest premium pricing. Analyst consensus is strongly bullish with a $68.00 price target, supported by innovation in brands like Oreo and Ritz. A dividend of $0.50 per share is scheduled for July 2026, enhancing income appeal amid stable cash flows.
Outlook remains positive due to consistent earnings outperformance and strategic brand initiatives, though risks include margin pressure from input costs and technical bearish indicators. The stock offers growth potential with a margin of safety from analyst targets, but investors should monitor Q2 2026 results on July 28 for volume growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
